TSPAN1 and prostate cancer: Analysis of previously published RNA-Seq data from before and after 7 days of androgen depletion in prostate cancer patients using Degarelix31 shows a significant reduction in TSPAN1 mRNA indicating a tissue based response (Fig. 1H).